front-line chemotherapy, the patient received high-dose chemotherapy with granulocyte colony-stimulating factor (G-CSF) stimulated autologous peripheral blood stem cell We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and (PBSC) transplantation. The conditioning regimen consisted of: cyclophosphamide 2 g/m 2 in 5% dextrose injecfacial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologtion USP (D5W) 500 cc i.v. over 2 h on days −6 to −4, thiotepa 240 mg/m 2 in 0.9% sodium chloride USP 250 cc ous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded to i.v. over 4 h on days −6 to −4, and BCNU 150 mg/m 2 in D5W 500 cc i.v. over 2 h on days −6 to −4. Day 0 reppain medications, including partial and complete opiate receptor agonists. Premedication of subsequent doses of resented the day of transplantation. During the infusion of BCNU, the patient developed a unilateral frontal crushing BCNU with corticosteroids, pain medications, or benzodiazepines lessened, but did not prevent the same sympheadache, circumoral paresthesia, photophobia, and facial flushing. The patient was treated with propoxyphene 130 toms from recurring. The incidence and mechanism of this toxicity are unknown, but this adverse syndrome mg p.o. and hydromorphone 1 mg i.v. which relieved the pain. Laboratory values were within normal limits. Subshould be considered when administering high-dose BCNU infusions.
tion. 1 Pulmonary complications are the most serious toxtation. BCNU was initially reconstituted in D5W 100 ml or 150 ml and infused over 40 min. However, the manufacicity, as their development is not predictable and often fatal. Approximately 1 to 6 months following BCNU therapy, turer reported intense skin flushing and conjunctival suffusion within 2 h of administration associated with rapid 31% of patients have developed a pulmonary syndrome characterized by sudden onset of progressive exertional intravenous infusion. This was related to the absolute alcohol diluent in each vial of BCNU. Consequently, subdyspnea and a slight dry cough, often with fever. 1 Ensuing infections by opportunistic pathogens, such as cytomegalosequent doses of BCNU were diluted in D5W 500 ml and infused over 2 h. Despite this change, an additional three virus, 4 and severe interstitial pneumonitis have been prevalent. 8 Pulmonary function tests (PFTs) have shown restricpatients developed the same adverse effects. Patients were treated with pain medications, including acetaminophen, tion, a reduced diffusing capacity for carbon monoxide, and hypoxemia.
1 Open-lung biopsy has revealed hypertrophy morphine, and hydromorphone. All but one patient responded to therapy by the end of BCNU infusion. The and hyperplasia of type II pneumocytes, active mononuclear cell infiltration and inflammation, and interstitial patients continued to receive subsequent doses of BCNU. Premedication with a combination of diphenhydramine, edema. 3 In contrast, chest radiographs have inconsistently revealed interstitial changes. 1 Despite resolution of clinical hydrocortisone, hydromorphone, lorazepam, or propoxyphene diminished the severity of subsequent reactions. symptoms, PFTs have often remained abnormal for extended periods, making PFTs important monitoring
The mechanism of toxicity is unknown but may be related to cytokine release. Increased concentrations of tools. 1 We report seven metastatic breast cancer patients who interleukin-6, tumor necrosis factor-␣, macrophage colonystimulating factor, and erythropoietin have been reported in developed adverse effects with high-dose BCNU never previously described in the literature (Table 1) . Four patients patients receiving CSF-primed peripheral blood progenitor cells after chemotherapy resulting in differences in platelet developed severe headaches, three experienced facial flushing, and all seven patients had circumoral paresthesia reconstitution and organ toxicity. 9 All of our reported patients received G-CSF stimulation for autologous periphwithin 90 min of the start of their first dose of BCNU. These patients received BCNU 150 mg/m 2 as part of their eral stem cell collection, but endogenous cytokine concentrations were not measured. These side-effects are also not conditioning regimen prior to autologous PBSC transplan-
